Cellectis (Paris:ALCLS), the genome engineering specialist, has announced the completion of a structurally important transaction concerning its subsidiary Cellectis bioresearch, which specializes in designing, developing and marketing products and services essentially for academic and biopharmaceutical industry researchers: a simplified legal structure, with Ectycell merged into Cellectis bioresearch; and a reinforced equity position, with a €3.5 million contribution subscribed for by Caisse des Dépôts.
Help employers find you! Check out all the jobs and post your resume.
